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Introduction: Recently, two studies revealed that MET amplifica-
tion was associated with secondary epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI) resistance in non-small cell
lung cancer (NSCLC) patients. But it remains uncertain whether
MET amplification could be related to primary TKI resistance in
NSCLC because of limited data.
Materials and Methods: MET gene dosage of the tumor tissues
from 208 NSCLC patients was investigated by real time quantitative
polymerase chain reaction and compared with molecular and clinical
features, including EGFR mutations, KRAS mutations, EGFR gene
copy numbers, and patient survivals. Three copies were used as the
cutoff. Among them, 25 patients were also evaluable for EGFR TKI
responsiveness.
Results: The proportion of high MET gene dosage was 10.58%
(22/208) with higher incidence in squamous cell carcinoma
(11.86%) and smokers (16.18%), although the differences with
adenocarcinoma and nonsmokers were nonsignificant. Coexisting
EGFR mutations were identified, and the incidence (8.54%) was
similar to wild type (12.0%). High MET gene dosage was signifi-
cantly associated with higher tumor stage (stage I  II versus stage
III  IV; p  0.0254) and prior chemotherapy for stage III  IV
adenocarcinoma patients (35.71% versus 7.41%; p  0.0145) but
not correlated with primary TKI resistance. Among the 155 surgi-
cally resectable patients (stage I to IIIA), highMET gene dosage was
significantly associated with shorter median survival (21.0 months
versus 47.1 months; p  0.042) by univariate analysis.
Conclusions: High MET gene dosage was not related to primary
TKI resistance and the incidence was increased after chemotherapy,
suggesting high MET gene dosage may also be related to chemo-
therapy resistance.
Key Words: MET amplification, EGFR, NSCLC, Tyrosine kinase
inhibitor, Chemotherapy, Gene dosage.
(J Thorac Oncol. 2011;6: 2027–2035)
MET gene (met proto-oncogene) was originally identifiedas a cellular counterpart of the chemically induced
oncogene tpr-met isolated from a human osteosarcoma cell
line.1 The MET gene encodes c-Met protein, which is the
receptor with highest affinity to hepatocyte growth factor
(HGF).2 HGF binding augments the intrinsic tyrosine kinase
activity of c-Met, resulting in autophosphorylation of several
tyrosine residues within the intracellular region.3 Signaling
via the c-Met–HGF/SF pathway has been shown to lead to an
array of cellular responses including proliferation (mitosis),
scattering (motility), and branching morphogenesis.4 More-
over, the abrogation of c-Met signaling by RNA interference
could lead to regression of the tumor and metastases.5 c-Met
overexpression had also been reported to be associated with
poor clinical outcome in various cancers, including non-small
cell lung cancers (NSCLC).6–8 The above results are support-
ive for c-Met protein as an important human oncoprotein.
MET gene also plays a central role in hereditary papillary
renal carcinoma, which is causally related to gain-of-function
germ line mutations in the MET gene tyrosine kinase do-
main.9 Gain-of-function MET gene mutations at juxtamem-
branous domain, but not in the tyrosine kinase domain, have
also been found in both small cell lung cancers (4/32, 12%),10
and NSCLCs (0–13%).11,12 But their clinical significance
remained uncertain. In addition to mutations, several reports
have shown genomic amplification ofMET occur in 5 to 10%
of gastric cancers and 4% of esophageal cancer.13–15 As for
NSCLC, before 2007, there was only one report about MET
gene amplification (by single-nucleotide polymorphism array
analysis) and the incidence was very low (1 in 70 NSCLC
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patients and none in 30 lung cancer cell lines).16 In year 2007,
two important studies revealed that MET gene amplification
were associated with secondary tyrosine kinase inhibitors
(TKI) resistance in NSCLC patients harboring epidermal
growth factor receptor (EGFR) mutations and originally re-
sponsive to the EGFR TKI treatment.17,18 MET gene analysis
of tumor samples from multiple independent patient cohorts
by Bean et al.18 reported a significant difference in the
proportion of MET gene amplification between the tumors
from NSCLC patients with acquired resistance to TKI treat-
ment (9/43, 21%) and tumors from TKI naïve NSCLC pa-
tients (2/62, 3%; p  0.007). Thus, it would suggest c-Met
protein could be a significant therapeutic target for NSCLC
patients with secondary resistance to TKI but not for TKI-
naive patients because of low incidence of MET gene ampli-
fication. Five recent studies19–23 on TKI naive NSCLC pa-
tient cohorts also reported similar low incidence ofMET gene
amplification (1.4–11.1%) as Bean et al.18 In contrast, one
study from France revealed a much higher incidence of MET
gene amplification (21%).24
Although MET gene amplification developed in pa-
tients with preexisting EGFR mutations after TKI treatment
has been well recognized,17,18,23 whether MET gene amplifi-
cation could coexist with EGFR mutations in TKI naive
patients was still controversial. Some studies revealed that all
MET gene amplification did not coexist with EGFR muta-
tions.20,23,24 But Cappuzzo et al. and Kubo et al.19,21,22 have
reported presence of increased MET gene copy number to-
gether with EGFR mutations, suggesting that these two ge-
netic aberrations are not mutually exclusive. It is also uncer-
tain whether increased MET gene copy number could be
related to primary TKI resistance in patient with NSCLC,
which was mainly because of small patient number with
increasedMET gene copy number in each study. Kubo et al.21
reported one patient withMET gene amplification and L858R
mutation and was TKI resistant. Cappuzzo et al.19 found four
patients with high MET copy numbers (2.91 copies) were
still TKI responders. Among the four patients, one patient
also had EGFR mutation.
Because there were no standard criteria or definition for
MET gene amplification, it might be one reason why there
were great variations of the incidence of MET gene amplifi-
cation in the published studies and their clinical features.
Among the eight publishedMET gene copy number studies in
NSCLCs, six used quantitative real-time polymerase chain
reaction (Q-PCR) to determine the MET gene copy number.
Because the definition of gene amplification should be gene
to the centromere ratio of at least two, it is probably more
appropriate to use the term “high MET gene dosage” instead
of “MET gene amplification” for studies using Q-PCR
method, because Q-PCR could not determine the MET gene
and centromere signal at the same time. In the gefitinib-
resistant lung cancer cell lines with high MET gene amplifi-
cation (HCC827 GR6 and H820), they usually have very high
copy numbers (six-nine copies per nuclei).17–19 However,
such high copy number was rare in human NSCLC specimens
and had not been used as the standard cutoff. Among the six
MET gene studies using Q-PCR to determine the MET gene
copy number (gene dosage), two use the mean copy num-
ber  two standard deviation of all specimens as the cutoff,
but the exact copy number data, including the cutoff were not
shown.23,24 Bean et al.18 used three copies as the cutoff.
Onozata et al.20 used two copies as the cutoff because
majority of tumors were all smaller than two copies. Kubo et
al.21 used five copies as the cutoff. The two reports from
Cappuzzo et al.19,22 used fluorescence in situ hybridization
(FISH) to count the MET gene copy number of the tumor
cells directly. They also use the mean copy numbers
(2.91 copies) as the cutoff in their first MET gene copy
number study in NSCLC.19 In their second study on 447
tissue array samples, they have analyzed various cutoff
from two copies to six copies and used  five copies as the
cutoff for survival analysis.22
To clarify the clinical implications of high MET gene
dosage in NSCLC, we have performed MET gene dosage
study by Q-PCR in 208 NSCLC patients without prior TKI
treatment. We decided to use three copies as the cutoff for
high MET gene dosage, because the cutoff in most of the
published studies used, either by Q-PCR or FISH, were all
below or equal to three copies.18–20,23,24 In addition, because
the tumor tissue always had small amount of normal stromal
cells (two copies) component, the actual tumor copy number
should be higher than the data obtained by Q-PCR using
whole tissue DNA. Thus, tumors had MET gene dosage 3
copies by Q-PCR should have more than three copies per
nucleus. Among the 208 patients in this study, TKI treatment
responses were evaluable in 25 adenocarcinoma (ADC) pa-
tients. KRASmutation, EGFRmutation, and EGFR gene copy
number data were also available in most of these patients.
MATERIALS AND METHODS
Patients and Tissues
Patients Received Surgical Resection
Fresh frozen tumor specimens obtained soon after re-
section and stored at 80°C from NSCLC patients receiving
surgical resection and with signed informed consent at
Chang-Gung Memorial Hospital from January 1996 to De-
cember 1998 and from May 2002 to May 2004 were obtained
from the tissue bank of Chang-Gung Memorial Hospital for
this study. The patients from May 2002 to May 2004 were the
same patient group of our first EGFR mutation study.25 The
specimens from 1996 to 1998 were a retrospective applica-
tion for the earliest fresh frozen NSCLC tumor tissue in the
tissue bank, mainly for comparison of the survival differences
of NSCLC patients of earlier years. The surgical specimens in
the tissue bank from January 1999 to April 2002 were not
applied for study because of limitation of research funds.
Patient with Advanced Stage Disease
(Pathology Stage IIIB-IV)
Fresh frozen tumor specimens of 33 stage IIIb and stage
IV lung ADC patients of a clinical trial testing gefitinib
responsiveness in EGFR-mutated NSCLC patients were ob-
tained by biopsy (one piece for pathology diagnosis and one
piece for molecular study) with signed informed consent.
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Most of these tissues were acquired from computed tomog-
raphy (CT)-guided core needle biopsy or from wedge resec-
tion of lung at the time of diagnosis. Four samples were from
craniotomy for brain metastasis, one was collected from
pleural effusion, and one from neck soft tissue biopsy. None
of these patients had received TKI treatment before the
biopsy. Fourteen of these 33 patients had prior chemotherapy
before biopsy.
Totally, 175 tumor specimens from surgical resection
and 33 from biopsy were included in this study. All these 208
patients had no TKI treatment before the operation or biopsy.
All clinicopathological information was obtained from the
medical records. The therapeutic protocols of all patients
were reviewed thoroughly for the analyses of patient survival.
The stage listed was the pathology stage according to Amer-
ican Joint Committee on Cancer (AJCC) guidelines, 6th
edition. Smoking status was defined as nonsmokers (never
smoke or 100 lifetime cigarettes) and ever smokers. The
death records were from the medical records or from Depart-
ment of Health of Taiwan. For patient who received surgery,
the overall survival (OS) was counted from the date of
surgery until death. For patients received EGFR TKI treat-
ment, the progression-free survival and OS were counted
from the first day of TKI treatment. The study protocol had
been reviewed and approved by the institutional review board
of Chang-Gung Memorial Hospital and National Health Re-
search Institutes.
Definition of Responsiveness to TKI Treatment
Among the 33 patients whose tumor specimens were
obtained by biopsy, 25 of the 33 patients received TKI
monotherapy treatment soon after the biopsy was done, and
TKI treatment response was evaluated. For patients having
prior antitumor treatment, they should have fully recovered
from toxic effects of previous antitumor therapy, no chemo-
therapy within 1 month before the TKI treatment, and with
adequate liver and renal function. For evaluation of the
TKI treatment response of the patients, plain chest x-ray
was taken every week for 4 weeks and at least monthly
thereafter. CT scan was performed at base line, day 14, day
56, and every 3 months thereafter. Response was evaluated
and classified as complete response (CR), partial response
(PR), stable disease (SD), and progressive disease (PD),
respectively, according to the Response Evaluation Crite-
ria in Solid Tumors (RECIST) criteria. The response pat-
terns were determined on day 56.
Quantitative Real-Time PCR (Q-PCR) for
Evaluation of MET Gene Dosage
Frozen sections stained with hematoxylin and eosin
was performed on all of the frozen tumor specimens first to
check for the tumor percentage. If the tumor percentage was
less than 60%, microdissection would be performed. Thus,
we could be sure that all tumor tissue for DNA extraction had
sufficient tumor component. Majority of tumor samples had a
tumor percentage 80% in this study. DNA extraction from
fresh frozen tumor tissue was then performed according to the
protocol published previously.25 Relative gene dosage of
MET gene were determined by Q-PCR. MTHFR (5,10-meth-
ylenetetrahydrofolate reductase, located at 1p36.3) was used
as endogenous control gene as reported previously.18 Expres-
sion were evaluated using the following primers:
MET-sense: 5-CCATCCAGTGTCTCCAGAAGTG-3;
MET-antisense: 5-TTCCCAGTGATAACCAGTGTGTAG-3;
MTHFR-sense: 5-CCATCTTCCTGCTGCTGTAACTG-3;
MTHFR-antisense: 5-GCCTTCTCTGCCAACTGTCC-3.
For this study, 20 ng of genomic DNA was amplified
for 45 cycles (10 seconds at 95°C, 5 seconds at 65°C, and 5
seconds at 72°C) in a LightCycler 1.5 instrument (Roche
Diagnostics GmbH, Mannheim, Germany), using the Light-
Cycler FastStart DNA MasterPlus SYBR Green I kit (Roche
Diagnostics) and 250 M of primers. Each sample was
performed in triplicate. The CT values were analyzed by
LightCycler analysis software 4.05 (Roche Diagnostics). The
DNA sample from peripheral blood of a healthy 24-year-old
male volunteer (Taiwanese) was used as the reference sample
(two copies). A549 lung cancer cell line had 1.5-fold in-
creases (three copies) of MET gene dosage and was used as
the positive control. This gene dosage (three copies per
nucleus) of A549 cell line was confirmed by FISH using the
Vysis LSI D7S522 (7q31)/CEP7 commercial probes (Abbott
Molecular, Inc., Des Plaines, IL).
For all samples, triplicate cycle time (CT) values were
averaged and normalized to MTHFR using the reference
DNA sample, and cutoff values for high MET gene dosage
were determined by using positive controls. Fold changes
were calculated using the equation 2CT, where CT 
(CT[MET]sample  CT[MTHFR]sample)  (CT[MET]refer-
ence DNA  CT[MTHFR]reference DNA).26 Gene dosage
higher than 1.5-fold (three copies) was considered to have
high MET gene dosage.18
MET Gene Copy Number Detection by FISH
The FISH detection was done on cultured A549 cell
line on coating slides or 4-m-thick paraffin-embedded for-
malin-fixed tissue sections on coating slides. The MET probe
used was the Vysis LSI D7S522 (7q31)/CEP7 commercial
probes (Abbott Molecular, Inc.). The deparaffinized forma-
lin-fixed tissue sections were first pretreated with 100 mM
Tris, 50 mM EDTA, pH 7.0 solution in 92°C for 15 minutes,
and then washed with phosphate-buffered saline (PBS). For
slides with cultured fresh A549 cell line, no pretreatment was
used. The slides were then digested with 300 L of Digest-all
(Zymed, Inc., South San Francisco, CA) at 37°C for 10 to 20
minutes depending on the size of the tissue sections. The
digestion was stopped by 10% neutral formalin at room
temperature for 1 minute and washed with PBS again. Ten
microliter of MET probe was applied to each dehydrated and
air-dried slide, and denatured at 94°C for 3 minutes, then
hybridized overnight at 37°C in VYSIS HYBrite (Abbott
Molecular, Inc.). Posthybridization washes were performed
with 0.5 standard saline citrate at 72°C for 5 minutes and
then rinsed in PBS with 0.25% Tween 20 (Sigma-Aldrich
Co., St. Louis, MO). The slides were then mounted with 10
l of VECTASHIELD mounting medium (Vector Laborato-
ries, Inc., Burlingame, CA) with DAPI. The FISH study
results were evaluated with Leica DMR fluorescence micro-
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scope (Leica Microsystems Nussloch GmbH, Nussloch, Ger-
many) and counted by two scientists (S.F.H., Y.T.C.). At
least 100 nonoverlapping and intact tumor nuclei were eval-
uated. The FISH images were taken by SPOT2 image system
(DIAGNOSTIC instruments, Inc., IL).
EGFR and KRAS Mutation Analyses
For EGFR mutation, PCR amplification of the coding
sequences from exons 18 to 21 followed by direct sequencing
were performed. For KRAS mutation, PCR amplification and
direct sequencing of exons 2 and 3 were performed. The
methodology of the above two studies were the same as
published previously.25,27 The data of the EGFR mutations
and KRAS mutations of the 175 surgical specimens had been
included in our previously published studies.27,29
EGFR Gene Copy Number Detection by
Chromogenic In Situ Hybridization
Determination of EGFR gene copy number was per-
formed by chromogenic in situ hybridization (CISH) on
paraffin sections of the tumor tissue. The methodology was
the same as mentioned previously.28 The EGFR probe used
was purchased from Zymed, Inc., South San Francisco, CA.
The EGFR gene copy number by CISH was performed in 150
patients and successful in 140 patients. All the 140 specimens
were from patients who received surgical resection. The gene
copy number was evaluated on at least 100 nonoverlapping
and intact tumor nuclei per specimen on a cell by cell level.
Because we have found significant association between high
EGFR gene copy number (5 copies) and EGFR mutation
previously,27 we have used the same cut line for EGFR gene
amplification to compare with the MET gene dosage data.
The EGFR gene copy number data of these 140 patients have
been included in our published study.27
Statistical Analysis
To examine the differences in the major clinicopatho-
logical features and molecular markers associated with high
MET gene dosage, the frequencies and proportions are com-
pared by conventional 2 association test or Fisher’s exact
test (when there is at least a cell frequency less than 5). A
two-sided p value less than 0.05 was considered statistically
significant. The differences in survivals were checked by
logrank tests. Multivariate analysis of OS was performed
using Cox’s regression model.
RESULTS
Clinical Characteristics Associated with High
MET Gene Dosage
The 208 NSCLC patients include 139 ADCs, 59 squa-
mous cell carcinomas, and 10 other types of NSCLCs. High
MET gene dosage were identified in 22 patients (10.58%).
Only 4 of the 22 patients had more than 4 copies of MET
gene. The major clinicopathological features and the molec-
ular markers associated with high MET gene dosage were
shown in Table 1. The proportion of high MET gene dosage
in squamous cell carcinoma was 11.86% (7 of 59), which was
similar to ADC (8.63%, 12 of 139). Only higher tumor stage
(stage I  II versus stage III  IV) was significantly asso-
ciated with high MET gene dosage (p  0.0254). Because 14
ADC patients (stage IIIB or IV) in this series had received
chemotherapy before the biopsy, we further analyzed the
clinical characteristics and high MET gene dosage status in
the 68 stage III and IV ADC patients (Table 2). The propor-
tion of high MET gene dosage was significantly higher in
patients with prior chemotherapy (5/14, 35.71%) than pa-
tients without (4/54, 7.41%; p  0.0145). Among the six
patients (five had prior chemotherapy) with specimens ob-
tained from metastatic lesions (four from brain, one from
neck, and one from pleural effusion), two had highMET gene
dosage (2/6, 33%). These two patients had received prior
chemotherapy.
Correlation of the MET Gene Dosage Results
Between Q-PCR and FISH
MET FISH performed on A549 cell line demonstrated
trisomy of both MET gene and chromosome 7 centromere
signals (Figure 1A). MET FISH were also performed on 10
patients with MET gene dosage higher than 1.5-folds and 5
patients with MET gene dosage lower than 1.5-folds. Totally,
TABLE 1. Clinical Characteristics of MET Gene Copy
Number Analysis in 208 NSCLC Patients
Clinical Characteristics
MET Gene Copy
Number 3
MET Gene Copy
Number <3 p
Total no. of patients (%) 22 (10.58) 186 (89.42)
Gender (%)
Male 14 (10.94) 114 (89.06) 0.8310
Female 8 (10.00) 72 (90.00)
Median age (range), (yr) 65 (50–79) 63 (29–84)
65 yr/0 (%) 11 (10.58) 93 (89.42) 1.0000
65 yr/0 (%) 11 (10.58) 93 (89.42)
Smoking historya (%)
Never 10 (8.20) 112 (91.80) 0.0935
Former 11 (16.18) 57 (83.82)
Histology type (%)
Adenocarcinoma 12 (8.63) 127 (91.37) 0.4813
Squamous cell carcinoma 7 (11.86) 52 (88.14)
Other 3 (30.00) 7 (70.00)
Stage (%)
I  II 7 (6.19) 106 (93.81) 0.0254
III  IV 15 (15.79) 80 (84.21)
EGFR polysomyb (%)
5 7 (10.94) 57 (89.06) 0.5381
5 6 (7.89) 70 (92.11)
EGFR mutationc (%)
Mutant 7 (8.54) 75 (91.46) 0.4302
Wild type 15 (12.00) 110 (88.00)
KRAS mutationd (%)
Mutant 0 (0.00) 6 (100.00) 1.0000
Wild type 21 (10.5) 179 (89.5)
a Eight patients without smoking history are not included.
b Sixty-eight patients without EGFR copy number data are not included.
c One patient without EGFR mutation data is not included.
d Two patient without KRAS mutation data are not included.
NSCLC, non-small cell lung cancer; EGFR, epidermal growth factor receptor.
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11 cases were successful in FISH (7 had gene dosages 1.5
folds and 3 had gene dosage lower than 1.5-folds) and 4 cases
failed. All tumors with high gene dosage had more than three
copies of MET gene per nucleus in more than 40% of tumor
cells (Figure 1B, C). The tumors with MET gene dosage
lower than 1.5-fold had two to three MET copies per nucleus
(Figure 1D, E). The above results were consistent with our
Q-PCR results. For the 33 patients with only biopsy speci-
mens (obtained for clinical trial), only 5 of them had available
paraffin sections. These biopsy specimens were quite small,
easily lost during digestion and denature process. Thus, the
FISH studies were not successful in these biopsy specimens,
which included the two patients with highest gene dosages
(increase for 8.805- and 2.960-folds).
EGFR and KRAS Mutations with High MET Gene
Dosage
All except one of the 208 patients also had EGFR
mutation data. The overall EGFR mutation rate was 39.6%
(82/207) and the mutation rate in ADC was 56.5% (78/138).
Seven of the 82 patients (7/82, 8.54%) with EGFR mutations
also had high MET gene dosage. The association showed no
significant difference with wild type EGFR (15/125, 12.0%;
Table 1). KRAS mutation analysis was performed in 206
patients. Only six patients had KRAS mutations (2.9%), and
none of them had high MET gene dosage (Table 1).
Increased EGFR Gene Copy Number and High
MET Gene Dosage
For patients with or without high EGFR gene copy
number (5 copies), the proportions of high MET gene
dosage were similar and showed no significant differences
(Table 1).
TKI Sensitivity and High MET Gene Dosage
Twenty-five patients received TKI monotherapy after
the biopsy were evaluable for TKI responsiveness. All of
them had ADC. There were 1 patient with CR, 16 patients
with PR, 4 with stable disease, and 4 with PD. The status of
EGFR mutation, high MET gene dosage and TKI response
patterns are shown in Table 3. All three patients having both
high MET gene dosage and EGFR mutations had PR after
TKI treatment. The MET gene dosages of these three patients
were 1.522-, 1.55-, and 1.6-folds, respectively (Figure 2). For
the two patients with high MET gene dosage and no EGFR
mutation, one had PD (the MET gene dosage was 1.765-
folds), and one had PR (the MET gene dosage were
8.805-folds, equivalent to more than 17 copies). In total,
there were five patients with high MET gene dosage, but
only one had PD. Thus, high MET gene dosage did not
show correlation with primary TKI resistance. EGFR mu-
tations remained to be TKI response predictor, because 16
of the 21 patients with EGFR mutations had CR or PR, and
only two patients had PD.
High MET Gene Dosage and Survival in
Surgically Resectable (Stage I to IIIA) NSCLC
Patients
We evaluated the high MET gene dosage and survival
only for patients with surgically resectable disease (stage I to
IIIA), because their therapeutic protocol were more uniform.
Among the 175 patients receiving surgical treatment, 12
patients with stage IIIB and stage IV disease and 4 patients
lost of follow-up were excluded. Totally 159 patients were
eligible for survival analysis. Among them, two patients died
of surgical complications and two patients died of other
causes (written on the death records) were further excluded.
Thus, totally 155 patients were included for the survival
analysis. All except one patient were functional class 1 in
performance status. The follow-up period ranged from 27
days to 158 months. None of these patients had received
chemotherapy before operation. The survival data of these
patients had been included in the survival analysis associated
with EGFR mutation study previously.29 Fifteen of the 155
patients (9.7%) had high MET gene dosage. The clinical and
molecular characteristics of the 155 patients are shown in
Table 4. The distribution patterns were similar to the 208
cases (Table 1), except that smoking status became signifi-
cantly associated with high MET gene dosage (p  0.035).
This might be related to the higher percentage of squamous
cell carcinoma (SCC) in these 155 patients, because SCC had
higher incidence of high MET gene dosage (6/51, 11.8%)
than ADC (5/93, 5.4%) and stronger association with smok-
ing. But SCC alone had no significant difference with ADC in
the proportion of high MET gene dosage (p  0.197). The
other types of NSCLCs, including adenosquamous carci-
noma, sarcomatoid carcinoma, large cell carcinoma and lym-
phoepithelioma-like carcinoma, also had significantly higher
proportion of highMET gene dosage (4/11, 36.4%) than SCC
and ADC (p  0.008), but the case number was too small for
further analysis.
TABLE 2. MET Gene Copy Number Analysis in 68 Stage
III–IV Adenocarcinoma Patients
Clinical Characteristics
MET Gene Copy
Number 3
MET Gene Copy
Number <3 pa
Total no. of patients (%) 9 (13.24) 59 (86.76)
Gender (%)
Male 2 (6.06) 31 (93.94) 0.1515
Female 7 (20.00) 28 (80.00)
Median age (range) (yr) 62 (50–79) 62 (39–82)
65 yr/0 (%) 6 (17.14) 29 (82.86) 0.4783
65 yr/0 (%) 3 (9.09) 30 (90.91)
Smoking history (%)
Never 7 (15.56) 38 (84.44) 1.0000
Former 2 (11.11) 16 (88.89)
Not available 0 (0) 5 (100)
Prior chemotherapy (%)
Yes 5 (35.71) 9 (64.29) 0.0145
No 4 (7.41) 50 (92.59)
EGFR mutation (%)
Mutant 5 (11.63) 38 (88.37) 0.7155
Wild type 4 (16.00) 21 (84.00)
a p value from Fisher’s exact test.
EGFR, epidermal growth factor receptor.
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The survival analysis revealed a significant better sur-
vival for patient without highMET gene dosage by univariate
analysis (Figure 3). The median survival for patients with and
without high MET gene dosage were 21.0 and 47.1 months,
respectively, (p  0.042). However, by multivariate analysis,
only patient age and disease stage were significantly associ-
FIGURE 1. MET FISH study with the Vysis LSI D7S522 (7q31)/CEP7 commercial probes (Abbott Molecular, Inc., Des Plaines,
IL). The MET gene had red signals and chromosome 7 centromere had green signals. A, A549 lung cancer cell line. The tumor
nuclei had three signals of both MET gene and the centromere. B, This tumor was a squamous cell carcinoma with no EGFR
mutation. The tumor nuclei had three to five signals of both MET gene and the centromere in more than 40% of tumor cells.
The MET gene dosage of this tumor was 1.587-folds. C, This tumor was an adenocarcinoma (ADC) with EGFR mutation (del
E746–A750). The tumor nuclei had four to seven signals of both MET gene and the centromere in more than 40% of tumor
cells. The MET gene dosage of this tumor was 1.585-folds. D, This tumor was a squamous cell carcinoma with no EGFR muta-
tion. The tumor nuclei had two to three signals of both MET gene and the centromere. The MET gene dosage of this tumor
was 1.236-folds. E, This tumor was an adenocarcinoma with no EGFR mutation. The tumor nuclei had two signals of both
MET gene and the centromere. The MET gene dosage of this tumor was 0.832-folds.
TABLE 3. High MET Gene Dosage and EGFR Mutation
Status in TKI Treated 25 ADC Patients
Treatment
Response
MET ()
EGFR ()
MET ()
EGFR ()
MET ()
EGFR ()
MET ()
EGFR ()
PR  CR (%) 3a (17.6) 1b (5.9) 13 (76.5) 0 (0.0)
SD (%) 0 (0.0) 0 (0.0) 3 (75.0) 1 (25.0)
PD (%) 0 (0.0) 1c (25.0) 2 (50.0) 1 (25.0)
Total number 3 2 18 2
a TheMET gene dosage of these three patients were 1.522-, 1.550-, and 1.600-folds,
respectively. The progression-free survival/overall survival were 6.87/15.87 mo, 11.93/
22.07 mo, and 20.17/27.5 mo, respectively.
b The MET gene dosage of this patient was 8.805-folds. The progression-free
survival was 2.47 mo, and overall survival was 6.0 mo.
c The MET gene dosage of this patient was 1.765-folds. The progression-free
survival was 1.58 mo, and overall survival was 10.5 mo.
EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; ADC,
adenocarcinoma; CR, complete response; PR, partial response; SD, stable disease; PD,
progressive disease (PD), according to the sixth JUCC criteria. FIGURE 2. MET gene dosages of the five adenocarcinoma
(ADC) patients with higher than three copies together with
normal and positive controls. Patients 1, 2, and 3 also had
EGFR mutation. Each column represents the mean 	 stan-
dard deviation for three independent experiments. The re-
sponse to EGFR tyrosine kinase inhibitor (TKI) treatment and
the gene dosage of each patient are shown on the top of
each column. NC, normal control; PC, positive control
(A549 cell line); PR, partial response; PD, progressive disease.
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ated with survival (Table 5). This might be due to higher
incidence of high MET gene dosage in stage IIIA patients,
although the incidence of highMET gene dosage of stage I
II patients (7/108, 6.5%) versus stage IIIA patients (8/47,
17.0%) alone were still nonsignificant (p  0.072). If we
performed multivariate analysis by using MET gene copy
number as a continuous variable, the results were quite
similar. The patient age and disease stage remained the only
two variables significantly associated with survival.
DISCUSSION
In this study, we investigated the MET gene dosage in
208 NSCLC patients and compared with various clinical
features and molecular markers. The proportion of high MET
gene dosage in this study was low (10.5%), which was similar
to previous reports.19–23 Coexisting EGFR mutations were
observed, and the frequency (9.76%) was similar to wild type
(11.2%), suggesting these two events occur independently.
None of the patients with high MET gene dosage had KRAS
mutations, which was also similar to previous reports.19–23
There was no significant correlation between EGFR gene
copy number changes and high MET gene dosage. The cutoff
TABLE 4. MET Gene Copy Number Analysis in 155
Surgically Resectable NSCLC Patients
Clinical Characteristics
MET Gene Copy
Number 3 (%)
MET Gene Copy
Number <3 (%) p
Total no. of patients 15 (9.7) 140 (90.3)
Gender
Male 13 (12.8) 89 (87.3) 0.089
Female 2 (3.8) 51 (96.2)
Median age (range) (yr)
65 yr/0 6 (7.9) 70 (92.1) 0.589
65 yr/0 9 (11.4) 70 (88.6)
Smoking historya
Never 5 (5.5) 86 (94.5) 0.035
Former 9 (18.0) 41 (82.0)
Histology typeb
Adenocarcinoma 5 (5.4) 88 (94.6) 0.008
Squamous cell carcinoma 6 (11.8) 45 (88.2)
Other 4 (36.4) 7 (63.6)
Stage
I  II 7 (6.5) 101 (93.5) 0.072
IIIA 8 (17.0) 39 (83)
EGFR polysomyc
5 6 (12.0) 44 (88.0) 0.761
5 6 (9.2) 59 (90.8)
EGFR mutationd
Mutant 3 (5.8) 49 (94.2) 0.389
Wild type 12 (11.8) 90 (88.2)
KRAS mutatione
Mutant 0 (0.0) 7 (100.0) 1.000
Wild type 15 (10.2) 132 (89.8)
p value: all by Fisher’s exact test.
a Fourteen patients had no smoking data were not included.
b If only compare the difference between adenocarcinoma and squamous cell
carcinoma, p  0.197.
c Forty patients without EGFR copy number data are not included.
d One patient without EGFR mutation data is not included.
e One patient without KRAS mutation data is not included.
NSCLC, non-small cell lung cancer; EGFR, epidermal growth factor receptor.
FIGURE 3. Kaplan-Meier curves for overall survival (OS) of 155
NSCLC patients with and without highMET gene dosage, respec-
tively. MET () for patient with MET gene copy number 3
and MET() for patients with MET gene copy number 3.
TABLE 5. Multivariate Survival Analysis of the 155
Surgically Resectable NSCLC Patients
Variables HR (p) 95% CI
MET copy No. 3 1.84 (0.147) 0.81–4.19
vs. 3 1.00
Gender  Male 0.79 (0.468) 0.41–1.50
vs. Female 1.00
Age 65 yr 3.07 (0.001) 1.80–5.25
vs. Age 65 yr 1.00
Smokers 1.54 (0.190) 0.81–2.95
vs. Non smokers 1.00
Pathology diagnosis
Squamous cell carcinoma 0.63 (0.211) 0.30–1.30
Others 0.57 (0.406) 0.15–2.17
vs. Adenocarcinoma 1.00
Stage  III 2.19 (0.009) 1.22–3.93
vs. I, II 1.00
EGFR copy No. 5 1.06 (0.863) 0.55–2.02
vs. 5 1.00
EGFR mutants 0.64 (0.250) 0.30–1.37
vs. wild type 1.00
KRAS mutants 1.23 (0.689) 0.45–3.40
vs. wild type 1.00
NSCLC, non-small cell lung cancer; EGFR, epidermal growth factor receptor; HR,
hazard ratio; CI, confidence interval.
Journal of Thoracic Oncology • Volume 6, Number 12, December 2011 High MET Gene Dosage in NSCLC
Copyright © 2011 by the International Association for the Study of Lung Cancer 2033
of high EGFR gene copy number was defined as 5 copies
in this study, which was different from the criteria (4
copies) used by most of the other reports on EGFR gene copy
number study.
When compared with survival of the 155 surgically
resectable patients, high MET gene dosage was significantly
associated with shorter median survival (21.0 versus 47.1
months, p  0.042) by univariate analysis (Figure 2),
whereas the stage distribution between patients with and
without high MET gene dosage was insignificant in this
cohort (0.072). This result was similar to the recent study by
Cappuzzo et al on a 447 patient cohort of western countries.22
We also analyzed the correlation between high MET
gene dosage and TKI response in 25 patients without previ-
ous TKI treatment. Our data revealed that patient with high
MET gene dosage could have either TKI response or TKI
resistance (Table 3). In addition, when highMET gene dosage
coexisted with EGFR mutations, all three patients in this
series remained to be TKI responders. Thus, high MET gene
dosage was not associated with primary resistance of TKI,
especially when it was associated with EGFR mutations. It is
intriguing why high MET gene dosage could be associated
with secondary TKI resistance, but not for primary resistance.
Because the mechanism of secondary TKI resistance caused
by high MET gene dosage was due to phosphorylation of
ERB3 and activation of PI-K3/AKT pathway.17 One possible
explanation for noncorrelation between high MET gene dos-
age and primary TKI resistance is that ErbB3 protein expres-
sion might be absent or very low in the TKI-naive NSCLCs.
Thus, high MET gene dosage alone would not be able to
provide survival advantage for these tumors. After long-term
TKI treatment, both ErbB3 protein expression and high MET
gene dosage might be gradually increased and resulted in
secondary resistance.
When we analyzed the association between clinical
characteristics and high MET gene dosage (Table 1), only
tumor stage (stage I  II versus III  IV) was significantly
associated with high MET gene dosage, which was quite
consistent with the functional roles of MET gene, such as
tumor cell migration and metastasis. Interestingly, when we
further analyzed the high MET gene dosage in stage III and
stage IV ADC patients, the proportion of high MET gene
dosage was significantly higher in patients with prior chemo-
therapy (5/14, 35.71%) than patients without (4/54, 7.41%;
p  0.0145). This phenomenon has never been reported
before. It could be because of tumor clone selection or
adaptation to the toxic effect of chemotherapy. This could
also explain why the clinical courses of NSCLC patients
usually become more aggressive after development of che-
motherapy resistance. Thus, to develop c-Met inhibitor is not
only promising for treatment of secondary EGFR TKI resis-
tance but might also useful for chemotherapy resistance.
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